|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 315.30 CHF | -0.76% |
|
+0.64% | +23.41% |
| 07:05am | Roche Says Lymphoma Treatment Lunsumio Might Be Effective Earlier | DJ |
| 06:53am | European Commission Approves Roche Lupus Nephritis Treatment | DJ |
Evolution of the Average Target: Roche Holding AG
Evolution of the Target Price: Roche Holding AG
Changes in Analyst Recommendations: Roche Holding AG
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +0.24% | |||||
| +6.65% | |||||
| +0.89% | |||||
| +9.16% | |||||
| +9.84% | |||||
| +1.2% | |||||
| +7.77% | |||||
| +30.7% | |||||
| +0.94% | |||||
| +7.79% | |||||
| Average | +7.52% | |||||
| Weighted average by Cap. | +6.64% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| JPMORGAN | Richard Vosser |
| UBS | Matthew Weston |
| BERENBERG | Luisa Hector |
| JEFFERIES | |
| BERNSTEIN RESEARCH | Justin Smith |
| alphavalue | Abhishek Raval |
| DZ BANK | Elmar Kraus |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| GOLDMAN SACHS | James Quigley |
| AlphaValue/Baader Europe | |
| Morgan Stanley | |
| HSBC | |
| Intron Health | |
| Kepler Cheuvreux | |
| Redburn | |
| Deutsche Bank Securities | |
| BARCLAYS | Emily Field |
| Nykredit Bank | |
| Stifel Nicolaus | |
| BNP Paribas | |
| Societe Generale | |
| CREDIT SUISSE | Dominic Lunn |
| Octagon Capital | |
| Kepler Capital Markets | |
| Vista Partners | |
| Berenberg Bank | |
| ODDO BHF | |
| International Strategy & Investment Group | |
| BANK OF AMERICA (BOFA) | Sachin Jain |
| Bryan, Garnier & Co. | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| Wolfe Research | |
| Jefferies & Co. | |
| Morgan Lewins & Co. | |
| Independent Research | |
| Dawson James | |
| Exane BNP | |
| Bernstein | |
| Dundee | |
| Banco Santander | |
| CITIGROUP | Andrew Baum |
| Liberum Capital |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROG Stock
- Consensus Roche Holding AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition